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Abbreviations 
BRET, Bioluminescence resonance energy transfer 
CAMYEL, cAMP sensor using YFP-EPAC-Rluc 
CB1, Cannabinoid receptor type 1 
CB1-KO, CB1-knock out 
CNS, Central nervous system 
CHO, Chinese Hamster Ovary, CHO 
GDP, Guanosine 5′-diphosphate 
GIRK, G-protein-coupled inwardly rectifying K
+
 channels 
GPCR, G-protein coupled receptor 
GTPγS, guanosine 5’-O-(3-thiotriphospate) 
HEK-293, Human Embryonic Kidney 293 
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ABSTRACT 
Rimonabant is a potent and selective cannabinoid CB1 receptor antagonist widely used in animal and 
clinical studies. Besides its antagonistic properties, numerous studies have shown that, at micromolar 
concentrations rimonabant behaves as an inverse agonist at CB1 receptors. The mechanism underpinning 
this activity is unclear. Here we show that micromolar concentrations of rimonabant inhibited Gαi/o-type G 
proteins, resulting in a receptor-independent block of G protein signaling. Accordingly, rimonabant 
decreased basal and agonist stimulated [
35S]GTPγS binding to cortical membranes of CB1- and GABAB-
receptor KO mice and Chinese Hamster Ovary (CHO) cell membranes stably transfected with GABAB or 
D2 dopamine receptors.  The structural analog of rimonabant, AM251, decreased basal and baclofen-
stimulated GTPγS binding to rat cortical and CHO cell membranes expressing GABAB receptors. 
Rimonabant prevented G protein-mediated GABAB and D2 dopamine receptor signaling to adenylyl 
cyclase in Human Embryonic Kidney 293 cells and to G protein-coupled inwardly rectifying K
+
 channels 
(GIRK) in midbrain dopamine neurons of CB1 KO mice. Rimonabant suppressed GIRK gating induced 
by GTPγS in CHO cells transfected with GIRK, consistent with a receptor-independent action. 
Bioluminescent resonance energy transfer (BRET) measurements in living CHO cells showed that, in 
presence or absence of co-expressed GABAB receptors, rimonabant stabilized the heterotrimeric Gαi/o-
protein complex and prevented conformational rearrangements induced by GABAB receptor activation. 
Rimonabant failed to inhibit Gαs-mediated signaling, supporting its specificity for Gαi/o-type G proteins. 
The inhibition of Gαi/o protein provides a new site of rimonabant action that may help to understand its 
pharmacological and toxicological effects occurring at high concentrations 
Key words: Bioluminescence resonance energy transfer (BRET), cannabinoid receptor type 1 (CB1), 
CB1-receptor antagonist, inverse agonist, G protein, G protein-coupled receptor (GPCR) 
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1. Introduction
Heterotrimeric guanine nucleotide binding proteins (G proteins) are primarily activated by G protein 
coupled receptors (GPCRs) that transduce extracellular stimuli from the cell surface to intracellular 
signaling cascades (Milligan and Kostenis, 2006; Denis et al., 2012; Syrovatkina et al., 2016). G protein 
signaling is regulated by “the regulator of G-protein-signaling” (RGS) proteins that activate the GTPase 
activity of the Gα subunits (Sato et al., 2006; Roman 2009; Sjögren et al., 2010, 2011). RGS proteins are, 
therefore, potential targets for therapeutic agents intended to prolong and enhance receptor-induced G 
protein signaling. There is also evidence that Gα or Gβγ subunits of the heterotrimeric G protein can be 
directly targeted by small molecules with potential therapeutic action (see Smrcka 2013 for a review). For 
example, the anti-helminthic drug suramin and some of its analogues were found to inhibit the exchange 
of GDP for GTP at Gα subunit (Smrcka 2013). Likewise, the cyclic depsipeptide YM-254890 stabilizing 
the GDP bound form of Gαq subunit (Freissmuth et al., 1996; Takasaki et al., 2004). This compound 
delineates a target site for the development of inhibitors of G protein signaling, which would be of 
therapeutic benefit in ovarian cancer treatment (Nishimura et al., 2010, Kan et al. 2010). Moreover, 
fluorescein analogues that bind with micromolar affinity to Gβγ subunit have been identified; one of these 
potentiated morphine analgesia in rats (Bonacci et al., 2006). Recently, Ayoub et al. (2009) have identified 
two imidazopyrazine derivatives (BIM-46174 and BIM-46187) that prevented the GPCR-induced 
activation of all the G protein families tested. The compound BIM-46174 displayed anti-proliferative 
activity while the compound BIM-46187, which binds to the Gαi2 subunit, induced pain relief (Prévost et 
al. 2006; Favre-Guilmard et al. 2008).  
Rimonabant, (SR, 141716A (N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-
methyl-1H-pyrazole-3-carboxamide hydrochloride) is a highly potent and selective cannabinoid receptor 
(CB1) antagonist (Ki= 1.98 nM) (Rinaldi-Carmona et al., 1994) that displays a plethora of 
pharmacological effects under several pathophysiological conditions, including obesity-related disorders 
(Van Gaal et al., 2005; Scheen et al., 2006; Pi-Sunyer et al. 2006; Padwal and Majuumdar 2007; Xie et al., 
2007), drug addiction (i.e., alcohol, nicotine) (Le Foll et al., 2008; Soyka et al., 2008; Beardsley et al., 
2009; Cahill and Ussher 2011) and anticancer effects in vitro (Flygare et al., 2005; Bifulco et al., 2007; 
Malfitano et al., 2007; Ciaglia et al., 2015). Rimonabant was approved as an anti-obesity treatment 
(Acomplia, European Public Assessment Report 2007) in more than 50 countries worldwide. Rimonabant 
counteracts an increased tone of endogenous cannabinoids responsible for excessive appetite and 
metabolic alterations associated with obesity. While the efficacy of rimonabant in weight reduction was 
demonstrated in a series of major reports, the meta-analysis of clinical studies has revealed that its 
beneficial effect on obesity was associated with adverse psychiatric events, including anxiety and 
depression, increased risk of suicidal ideation and suicide attempts (Christensen et al., 2007; Rucker et al., 
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2007; Moreira et al., 2009). Due to these adverse effects rimonabant was withdrawn from the market in 
2009.  
Besides being a potent and selective CB1 receptor antagonist, rimonabant at nanomolar 
concentrations exhibits CB1-dependent inverse agonistic effects, including the inhibition of basal GTPγS 
binding (Lansdsman et al., 1997; MacLennan et al., 1998; Pertwee 2005; Howlett et al., 2011). In addition, 
numerous studies indicated that rimonabant at micromolar concentrations reliably inhibits GTPγS binding 
also in the presence or absence of CB1 receptors, both, in rodent and human brain tissues as well as in 
heterologous system (Sim-Selley et al., 2001; Breivogel et al., 2001; Savinainem et al., 2003; Cinar and 
Szücs 2009; Erdozain et al., 2012, Pertwee 2005). Several explanations have been proposed for the CB1-
independent inverse agonist activity of rimonabant, but the mechanism is still highly debated (Pertwee 
2005; Howlett et al., 2011; Raffa and Ward 2012).  
Here we demonstrate that at micromolar concentrations, higher than those commonly used to 
block the CB1 receptor, rimonabant inhibited activation of heterotrimeric G protein by acting at the Gαi/o 
subunit. Accordingly, rimonabant produced a receptor-independent reduction of basal activity of Gαi/o, 
prevented GPCR-mediated activation of Gαi/o proteins and signaling to their effectors. BRET experiments 
support that rimonabant induced conformational changes in heterotrimeric G protein. Our study identifies 
a new site of action of rimonabant thereby indicating that micromolar concentrations inhibit Gαi/o-type G 
proteins. 
2. Matherial and Methods
2.1 Animals—All procedures and experiments were carried out according to Italian (D.L. 26/2014) and 
European Council directives (63/2010) and in compliance with the approved animal policies by the 
Ethical Committee for Animal Experiments (CESA, University of Cagliari) and the Italian Department of 
Health. All possible efforts were made to minimize animal pain and discomfort and to reduce the number 
of experimental subjects. Male Sprague Dawley rats and DBA mice (Harlan Nossan, San Pietro al 
Natisone, Italy), weighing 200 to 250 and 17 to 20 g, respectively, were used. GABAB1 knockout 
(GABAB1-KO) and CB1-KO mice were obtained and genotyped as previously described (Schuler et al., 
2001; Marsicano et al., 2002). Rats and mice were housed 4 and 6 per cage, respectively, in a temperature- 
and light-controlled room. Light was on a 12-h cycle, and food and water were available ad libitum. 
2.2 Drugs and plasmid constructs—Guanosine 5′-diphosphate (GDP) and guanosine 5′-O-(3-
thiotriphosphate) (GTPγS) were purchased from Sigma/RBI (St.Louis, MO, USA). [35S]GTPγS (125 
Ci/mM) and [
3
H]CGP54626 (85 Ci/mM) were obtained from PerkinElmer and American Radiolabeled 
Chemicals Inc. (St. Louis, MO, USA), respectively. Luciferase substrate, Coelenterazine, was purchased 
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from NanoLight Technologies (US), Lipofectamine 2000 transfection reagents were obtained from 
Thermo Fisher Scientific (Waltham, MA). CGP54626, (R)-baclofen, quinpirole and A68293 were 
purchased from Tocris Bioscience (Ellisville, MO, USA). Rimonabant was a generous gift from G. Le Fur 
(Sanofi-Aventis Recherche, France), while the structural analog AM251 N-(Piperidin-1-yl)-5-(4-
iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide was purchased from Tocris 
Bioscience (Ellisville, MO, USA). Drugs were dissolved in 100 % DMSO and then diluted in an assay 
buffer. The concentration of DMSO used in the different assays never exceeded 0.1% (v/v) and had no 
effects on [
3
H]CGP54626 and [
35S]GTPγS binding assay, electrophysiological recordings and BRET 
measurements. Specifically, rimonabant or other drugs were dissolved at a concentration of 0.1 M in 
100% DMSO (stock solution) and diluted in buffer to obtain the working solution, i.e. dilution 1/1000 to 
obtain the final concentration of 0.0001 M of drug in buffer containing 0.1 % of DMSO.   
The plasmid pcDNA3L-His-(cAMP sensor using YFP-Epac-RLuc) (CAMYEL, MBA-277)  (Jiang et al., 
2007) was purchased from ATCC.  
Gαo-Rluc, Gγ2-Venus, Gβ1-Flag, Gγ2-HAwere a kind gift from Jean Philippe Pin (Institute of 
Functional Genomics, Montpellier, France), myc-GABAB1a and myc-GABAB2 were obtained as 
previously described (Pagano et al., 2001). The Gβ1-Rluc and Gγ2-Rluc constructs were produced by 
inserting the coding sequence of humanized Rluc into Gβ1 and Gγ2 (Fritzius et al., 2016). HA-D1 and HA-
D2 encoding for the human D1dopamine receptor and for the mouse D2 dopamine long receptor, 
respectively, were a kind gift from Bernd Fakler (University of Freiburg, Freiburg, Germany). Gαi1 91-
Venus, Gαi1 121-Venus and Gαi1 60-Venus constructs, which consisted in Venus A206K inserted between 
residues 60 and 61, 91 and 92 or 121 and 122 of human Gαi1 C351G were a kind gift from Nevin Lambert 
(Medical College of Georgia, Augusta, USA).  
2.3 Cell culture and transfection of CHO-K1 and HEK-293 cells—For the [35S]GTPγS binding assay, 
CHO-K1 cells were cultured to 80% confluency (3x10
6
 cells in 100-mm dishes) in DMEM supplemented 
with 500 µM L-glutamine (Sigma-Aldrich, Milan, Italy) and 10% FBS in a humidified atmosphere of 5% 
CO2 at 37°C. Then cells were incubated for 6 h with 30 µg of pcDNA3.1 (Zeo) plasmid containing the 
cDNA encoding for the human D2 dopamine long receptor (a kind gift from Olivier Civelli, Dept. of 
Pharmacology, University of California, USA) and 60 µl of Lipofectamine reagent in serum-free Opti-
MEM. Selection antibiotic (300 μg/ml zeocin) was added to the cell culture medium 48 h after 
transfection, and surviving colonies were harvested 14 days later. To confirm D2 long expression, 
competition and saturation binding experiments using [
3
H]YM09151-2, aspecific D2 receptor antagonist, 
were performed as previously described (Vanhauwe et al., 1999). The clone expressing the highest level 
of D2 receptors was selected and designated CHO-D2, maintained in DMEM containing 300µg/ml zeocin 
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and used throughout the study. For BRET measurements, culture and maintenance of CHO-K1 cells stably 
expressing GABAB1b and GABAB2 (CHO-GABAB) were performed and maintained as described (Urwyler 
et al., 2001). HEK-293 cells were cultured in DMEM supplemented with 10% FBS in a humidified 
atmosphere of 5% CO2 at 37°C. Transient transfections in CHO-GABAB and HEK-293 were performed 
with different plasmids encoding RLuc and YFP fusion proteins (see figure legends) and were carried out 
using Lipofectamine 2000 according to the manufacturer’s protocol. 
2.4 Binding studies  
2.4.1 [
35S]GTPγS binding assay in rat/mice membranes and in CHO, CHO-GABAB and CHO-D2 cell
membranes—GABAB-stimulated [
35S]GTPγS binding in rat/mice membranes was carried out as
previously described (Castelli et al., 2012). For CB1-stimulated [
35S]GTPγS binding, cortical membranes 
(10-15 µg of proteins) were incubated in an assay buffer (50 mM Tris-HCl, 3 mM MgCl2, 0.2 mM EGTA 
and 100 mM NaCl, BSA 0.1%, pH 7.4) at 30°C for 1 h with 30 µM GDP and 0.05 nM [
35S]GTPγS in a 
final volume of 1 ml. After incubation, the samples were filtered using a PerkinElmer UniFilter-GF/B, 
washed twice with 1 ml of buffer and dried for 1 h at 30°C. For D2-stimulated [
35S]GTPγS binding, 
striatal membranes (20 µg of proteins) were pre-incubated in an assay buffer (20 mM K-HEPES, 7 mM 
MgCl2, 1 mM EDTA, 1mM DTT and 100 mM NaCl, pH 7.6) at RT for 30 min with 300 µM GDP. The 
main incubation was subsequently started by the addition of [
35S]GTPγS to a final concentration of 0.1 nM 
in a volume of 300 µl. After 60 min of incubation at 35 °C, the samples were filtered using a PerkinElmer 
UniFilter-GF/B, washed twice with 1 ml of buffer (20 mM K-HEPES and 100 mM NaCl, pH 7.6), and 
dried for 1 h at 30°C. For CHO-GABAB stimulated [
35S]GTPγS binding, membranes (20 µg of proteins)
were incubated in an assay buffer (50 mM Tris-HCl, 10 mM MgCl2, 0.2 mM EGTA and 100 mM NaCl, 2 
mM CaCl2, pH 7.7) at 22-24°C for 1 h with 30 µM GDP and 0.2 nM [
35S]GTPγS in a volume of 0.3 ml.
After incubation, the samples were filtered using a PerkinElmer UniFilter-GF/C, washed twice with 1 ml 
of buffer and dried for 1 h at 50°C (Urwyler et al. 2001).  For CHO-D2 and CHO non-transfected cells 
stimulated [
35S]GTPγS binding, membranes (10 µg of proteins) were pre-incubated in an assay buffer (50 
mM K-HEPES, 10 mM MgCl2,100 mM NaCl, 0.1% BSA, pH 7.4) for 30 min at 30°C with 10 µM of 
GDP. The main incubation was subsequently started with the addition of [
35S]GTPγS to a final 
concentration of 0.1 nM. After 90 min incubation at 30°C, the samples were filtered using a PerkinElmer 
UniFilter-GF/B, washed twice with 300 µl of buffer 50 mM HEPES, pH 7.4, and dried for 1 h at 30°C. 
The radioactivity on the filters was counted in a liquid microplate scintillation counter (TopCount NXT; 
PerkinElmer Life and Analytical Sciences) using 50 µl of scintillation fluid (Microscint 20; PerkinElmer 
Life and Analytical Sciences). The stimulation by the agonist was defined as the percentage increase 
above basal levels (i.e. [disintegrations per minute (agonist) - disintegrations per minute (no 
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agonist)/(disintegrations per minute (no agonist)] × 100). Data are reported as the mean SEM of three to 
six experiments, performed in triplicate. Nonlinear regression analysis of concentration-response data was 
performed using Prism 2.0 software (Graph Pad Prism) to calculate Emax and EC50 values. 
2.5 BRET Measurements  
2.5.1 BRET measurements of G-protein activity in CHO-GABAB and in HEK-293 cells—CHO-GABAB 
cells were transfected with plasmids encoding Gαo-Rluc, Gγ2-Venus, Gβ1-Flag and after 6 h were seeded 
into 96-well microplates (Costar Corning Incorporated; coated with poly-L-ornithine hydrobromide; 
P3655, Sigma-Aldrich). HEK-293 cells were transiently transfected with plasmids encoding Rluc and 
YFP fusion proteins (see figure legends) and after 6 h were plated into 96-well microplates. 24 h after 
transfection, both the transfected CHO-GABAB and the HEK-293 cells were washed twice with PBS, and 
incubated at 37°C for 1 h with PBS containing rimonabant or the vehicle. Measurement was initiated 
using an Infinite® F500 microplate reader (Tecan, Switzerland) after 10 minutes of incubating the 
luciferase substrate (5 μM, Coelenterazine h, NanoLight Technologies). Baclofen (10 μM) was applied 
after 29 cycles of reading (≈25 sec) to CHO-GABAB cells. Luminescence and fluorescence signals were 
detected sequentially with an integration time of 200 ms. The BRET ratio was calculated as the ratio of 
light emitted by Venus (530–570 nm) over the light emitted by RLuc (370–470 nm) and corrected by 
subtracting ratios obtained with the Rluc fusion protein alone. The results were expressed in mBRET units 
(BRET x 1000). The curves were fitted using GraphPad Prism 5.0 (“plateau followed by one-phase 
decay”). ΔBRET was calculated as the difference between the basal and the plateau of the BRET signal. 
2.5.2 BRET measurements of cAMP responses using the YFP-Epac-RLuc (CAMYEL) sensor—HEK-293 
cells were transiently co-transfected with pcDNA3L-His-CAMYEL and with myc-GABAB1a and myc-
GABAB2, or with HA-D2, or HA-D1 plasmids. 6 h later, cells were distributed into 96-well microplates, 
and 24 h after transfection, were washed twice with PBS and pre-incubated at 37°C for 1 h with PBS 
containing rimonabant or the vehicle. The measurement was initiated using the Infinite® F500 microplate 
reader (Tecan, Switzerland) after 10 minutes of incubation with the luciferase substrate (5 μM, 
Coelenterazine). On HEK-293 transfected with GABAB or D2 receptor, forskolin (0.5 μM) was applied 
after 150 seconds of reading to stimulate cAMP production. Then, either baclofen (10 μM) or quinpirole 
(10 μM) was applied after 500 seconds of reading. On HEK-293 transfected with D1 receptor A68293 was 
applied after 150 seconds of reading. Luminescence and fluorescence signals were detected sequentially 
with an integration time of 200 ms. The BRET ratio was calculated as the ratio of light emitted by YFP 
(530–570 nm) over the light emitted by RLuc (370–470 nm). The curves were fitted using GraphPad 
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Prism 5.0 (“plateau followed by one-phase decay or by one-phase association”). ΔBRET was calculated as 
the difference between the basal and the plateau of the BRET signal. 
 
2.6 Electrophysiology 
2.6.1 Whole-cell voltage clamp recordings from dopamine neurons— Whole-cell patch-clamp recordings 
from midbrain dopamine cells were as previously described (Melis et al. 2010). Briefly, male Sprague 
Dawley rats or CB1-KO out mice were anesthetized with halothane and killed. Recordings were made 
from horizontal slices superfused with artificial cerebrospinal fluid (ACSF, 37° C), saturated with 95% O2 
and 5% CO2 containing (in mM): 126 NaCl, 1.6 KCl, 1.2 NaH2PO4, 1.2 MgCl2, 2.4 CaCl2, 18 NaHCO3 
and 11 glucose. Voltage-clamp experiments were performed with electrodes filled with a solution 
containing the following (in mM): 144 KCl, 10 HEPES, 3.45 BAPTA, 1 CaCl, 2.5 Mg2ATP, and 0.25 
Mg2GTP (pH 7.2–7.4, 275–285 mOsm). Experiments began after series resistance had stabilized 
(typically 15–40 MΩ). Series and input resistance were continuously monitored on-line with a 5 mV 
depolarizing step (25 ms). Data were filtered at 2 kHz, digitized at 10 kHz, and collected on-line with 
acquisition software (pClamp10.6, Molecular Devices). Dopamine neurons from lateral portion of  
posterior VTA were identified by the presence of a large Ih current (Johnson et al., 1992) that was assayed 
immediately after break-in using a series of incremental 10 mV hyperpolarizing steps from a holding 
potential of -70 mV. Each slice received one single drug exposure. All the drugs were dissolved in DMSO. 
The final concentration of DMSO was < 0.01 %. Statistical significance was assessed using a paired t test 
(with Welch’s correction). 
 
2.6.2 Whole-cell patch-clamp recordings from CHO cells—CHO cells were transfected with cDNAs 
encoding the GIRK 1/2 concatemer (Kaupmann et al., 1998) using Lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s instructions. 48 h after transfection experiments on CHO cells were 
performed at room temperature as previously described (Turecek et al., 2014). During recording, CHO 
cells were continuously superfused with an extracellular solution composed of (in mM): 145 NaCl, 2.5 
KCl, 1 MgCl2, 2 CaCl2, 10 HEPES, 25 Glucose; pH 7.3, 323 mOsm. Patch pipettes had resistances 
between 3-4 MΩ when filled with intracellular solution composed of (in mM) 107.5 potassium gluconate, 
32.5 KCl, 10 HEPES, 5 EGTA, 4 Mg ATP, 0.6 Li4GTPγS, 10 Tris phosphocreatine; pH 7.2, 297 mOsm. 
Series resistance (< 5 MΩ) was compensated by 80%. Kir3 responses induced by GTPγS were recorded 
with an Axopatch 200B patch-clamp amplifier (Molecular Devices, USA); filtering and sampling 
frequencies were set to 1 kHz and 5 kHz, respectively. Data analyses were done with pClamp 10 
(Molecular Devices, USA). Data are given as mean ± SD. Statistical significance was assessed using a t-
test. Rimonabant was dissolved in 100% DMSO and then diluted in an extracellular solution at a final 
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concentration of 10 μM. The final concentration of DMSO was 0.1 %, which was the same in the vehicle. 
Before the recording, CHO cells were pre-incubated in the extracellular solution either in the presence of 
the drug or the vehicle for 45 minutes at room temperature (22 - 24°C). 
2.7 Statistical Analysis—Data were expressed as the mean ± SEM and statistically evaluated by an 
unpaired t-test or by one-way ANOVA followed by the Bonferroni or Tukey test for multiple comparisons 
with significance for p < 0.05.  
3 RESULTS 
3.1 Rimonabant inhibits constitutive and agonist stimulated G protein activity—The effects of rimonabant 
on G protein basal activity was evaluated using [
35S]GTPγS binding assays in striatal or cortical 
membranes of rodents and membranes of CHO cells stably transfected with GABAB or D2 receptor as 
well as untransfected CHO cells. As shown in Table 1, rimonabant dose dependently reduced basal 
[
35S]GTPγS binding with a similar potency to cortical and striatal membranes of rats, as to cortical 
membranes of both CB1-KO and GABAB-KO mice and their wild-type littermates. Rimonabant also 
decreased, in a concentration-dependent manner, G protein basal activity in CHO cells expressing the 
GABAB or D2 receptor and in untransfected CHO cells (Table 1). Neither the GABAB receptor agonist 
baclofen (100 µM) nor the CB1 receptor agonist CP55,940 (100 μM) had any effect on [35S]GTPγS 
binding in untransfected CHO cell membranes, indicating that CHO cells do not express endogenous 
GABAB or CB1 receptors (data not shown). The inhibitory effect of rimonabant was observed at 
concentrations of GDP and NaCl that allow a constant and significant reduction in basal [
35S]GTPγS, as 
previously reported (Sim-Selley et al., 2001). However, in contrast to previous studies (Lansdsman et al., 
1997; MacLennan et al., 1998; Howelett et al., 2011), rimonabant at 10 and 100 nanomolar concentrations 
failed to inhibit basal [
35S]GTPγS binding (100.3 % ± 2 and 93 % ± 5 over basal activity, respectively).  
The effect of rimonabant on the stimulation of [
35S]GTPγS binding by baclofen and the D2 receptor 
agonist quinpirole was measured in rat and mouse cortical membranes. As shown in Fig. 1A at 5 µM 
concentration rimonabant induced a rightward shift in the concentration-response curve of baclofen-
induced stimulation of [
35S]GTPγS binding, resulting in a significant increase in EC50 (Table 2). However,
while this concentration had no effect on the maximal efficacy (Emax) of baclofen (Table 2), both the 
potency and the Emax were reduced by a concentration of 25 µM (Suppl. Fig. 1). The pEC50 moved from 
5.15 ± 0.06 (EC50 = 7.30 ± 1.10 μM) to 3.95 ± 0.10 (EC50 = 119 ± 24.85 μM)  (p< 0.05 and p < 0.001, 
respectively) and the Emax was reduced from 201 ± 10 % to 132 ± 7 % (p < 0.05). 
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An increase in the EC50 of baclofen was also observed with 5 µM of rimonabant in cortical membranes of 
CB1-KO mice (Fig. 1B, Table 2) and of its wild-type littermates (data not shown). These results indicate 
that the inhibitory effect of rimonabant on baclofen-induced G protein activation is CB1 receptor-
independent. Moreover, similarly to what observed with baclofen, 5 μM rimonabant reduced the potency 
of quinpirole in inducing [
35
S]GTPγS binding (Fig. 1C, Table 2), but failed to modify quinpirole efficacy.  
Altogether, these data confirmed that the inhibitory effect of rimonabant on Gi/o protein activity is not 
selective for a particular GPCR. Moreover, up to a concentration of 1 mM, rimonabant failed to inhibit the 
binding of the specific GABAB receptor antagonist [
3
H]CGP54626 to rat cortical membranes (data not 
shown), ruling out the action of rimonabant at the GABAB receptor itself.  
As fig. 2 shows, the structural analog of rimonabant AM251 at 10 μM significantly decreases basal 
GTPγS binding both in rat cortical (Fig 2A) and in CHO cell membranes stably expressing GABAB 
receptors (Fig 2B).  Moreover, as shown in Fig. 2C, in rat cortical membranes AM251 also inhibited the 
[
35S]GTPγS stimulation induced by a submaximal concentration (10 μM) of the GABAB receptor agonist 
baclofen. No significant difference in the ability to decrease basal and GABAB-stimulated G protein 
activity was observed between AM251 and rimonabant.  
Next, we used a BRET approach in CHO-GABAB cells to evaluate the influence of rimonabant on 
the conformational changes between Gαo-RLuc and Gγ2-Venus before and after GABAB receptor 
activation (Fig. 3A). As shown in Fig. 3B and C, rimonabant increased the basal BRET signal measured 
between Gαο-RLuc and Gγ2-Venus subunits in a concentration-dependent manner. Additionally, 
rimonabant reduced the magnitude of BRET changes during baclofen-induced G protein dissociation 
(Suppl. Fig. 2A) in a concentration-dependent manner, thus leading to a significant decrease in ΔBRET 
(Fig. 3D). These data suggest that rimonabant, independently of GABAB receptor activation, stabilizes the 
heterotrimeric state of the G protein and inhibits G protein activation. These effects of rimonabant were 
specific, since it did not directly alter Rluc activity for the duration of the experiments, even at a 
concentration of 50 μM  (Suppl. Fig 2B). 
3.2 Rimonabant inhibits GPCR signaling pathways—The effect of rimonabant on the signaling of GABAB 
and D2 receptors, which share a pool of Gi/o proteins, was evaluated by monitoring in real time 
intracellular cAMP production in living cells using the CAMYEL sensor (Jiang et al. 2007; Porcu et al., 
2016). BRET signal was recorded for 150 seconds to monitor basal cAMP production in HEK-293 cells 
co-transfected with CAMYEL and GABAB receptor (Fig 4A). Forskolin (0.5 μM) was added to stimulate 
cAMP production, resulting in a conformational change in the CAMYEL recorded as a decrease in BRET. 
The addition of baclofen reduced forskolin-stimulated cAMP production, as indicated by the increase in 
BRET. Rimonabant reduced baclofen-mediated inhibition of cAMP production, corresponding to a faster 
12 
and enhanced CAMYEL activation compared to the control (vehicle-pretreated), as indicated by the 
decrease in the time constant (t) of CAMYEL activation (Fig. 4B) and ΔBRET (Fig. 4C). 
As observed for the GABAB receptor, rimonabant also reduced the quinpirole-induced t of 
CAMYEL activation and ΔBRET, indicating that it decreased the quinpirole-induced inhibition of cAMP 
formation in HEK-293 cells expressing the D2 receptor (Fig. 4D-F). These results indicate that 
rimonabant reduces Gi/o mediated inhibition of cAMP production induced by GABAB and D2 receptor 
agonists. Moreover, rimonabant did not significantly alter (p>0.05 vs vehicle-pretreated) the forskolin-
induced BRET signal before baclofen or quinpirole stimulation, indicating that it does not directly inhibit 
adenylyl cyclase but instead inhibits Gi/o-protein signaling. To address whether rimonabant specifically 
inhibits Gi/o-proteins, its effect on Gs-mediated cAMP activation by the D1 selective receptor agonist 
A68293 was evaluated. In HEK-293 cells co-expressing the CAMYEL and the D1 receptor, rimonabant 
failed to modify A68293-induced activation of cAMP as measured by a decrease in BRET (Fig. 5) 
indicating that rimonabant does not inhibit Gαs-dependent cAMP formation. 
Whole-cell voltage-clamp (Vholding= -70 mV) recordings from midbrain dopamine neurons in acute rat 
brain slices ex vivo were performed to evaluate the effects of rimonabant on baclofen- and quinpirole-
induced outward K
+ 
currents (Lacey et al., 1988; Jiang et al., 1993). As shown in Fig. 6A, baclofen 
application (10 µM) induced an outward K
+
 current activated by the GABAB receptor (160.5± 29 pA, n=6)
that is reproducible upon repeated applications over time (Lacey et al., 1988; Jiang et al., 1993). However, 
when the slice was pretreated with rimonabant (10 µM), baclofen- induced outward current was abolished 
(31.7± 26.9 pA, n=6; p= 0.004; Fig. 6B). The CB1 receptor was not required for the rimonabant-induced 
blockade of GABAB-induced current, since rimonabant also prevented the baclofen-induced current in 
CB1-KO mice (14.7± 8.6 vs. 134.9± 6.6 pA in the presence and absence of rimonabant, respectively; n=3, 
p=0.0002; Fig. 6C). Moreover, rimonabant pretreatment abolished the D2 receptor-mediated outward 
current induced by quinpirole (1 µM) bath application (143.0± 41.4 vs. 13.9± 8.0 pA in the absence and 
presence of rimonabant, respectively; n=5, p=0.03; Fig. 6D). 
As Fig.6 shows the structural analog of rimonabant AM251, acting as CB1 antagonist and inverse agonist 
at low and high concentrations, respectively, prevented baclofen-induced outward current (20 µM: 55.2 ± 
19.2 pA, n=5; p= 0.0018; Fig. 6F) in a dose-dependent fashion (2 µM: 117.5 ± 21.5 pA, n=6E; p= 0.14; 
Fig. 6E). 
3.3 Rimonabant inhibits GTPγS induced GIRK channel gating—To evaluate whether rimonabant blocked 
GIRK activation by directly acting at the G protein, whole-cell patch-clamp recordings were performed in 
CHO cells transfected with GIRK1/2. GIRK currents were activated in a receptor-independent manner by 
GTPγS perfused into the cell via the recording pipette (Fig. 7A). GTPγS, exchanged for GDP at the Gα 
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subunit constitutively activates the G protein and leads to Gβγ subunit release that, in turn, activates GIRK 
channels (Logothetis et al., 1987). In the absence of rimonabant, GTPγS-induced inwardly rectifying K+ 
currents that reached their peaks within 2 to 3 minutes of recording and exhibited modest desensitization 
over the 10 min recording period (Fig. 7AB). Rimonabant (10 μM) significantly prolonged the rise time of 
K
+
 currents and reduced their maximal amplitudes (Fig. 7AB). These observations are consistent with 
rimonabant inhibiting G protein signaling and suggest a direct interaction of rimonabant with G protein 
subunits. 
3.4 Rimonabant induces conformational changes in the heterotrimeric G protein—To investigate whether 
rimonabant induced BRET changes within the heterotrimeric G protein in the absence of receptors, we 
used HEK-293 cells transfected with Gαi1 tagged with Venus and Gβ1 or Gγ2 tagged with RLuc. The RLuc 
tag was inserted at the C-terminus of Gβ1 or Gγ2 (Fig. 8A), where it does not affect the function of the Gβγ 
dimer (Gales et al., 2006). We used several Gαi1 constructs, with Venus tags inserted into connecting loops 
at opposite ends of the helical domains (Fig. 8A). Venus was inserted into the loop connecting helices A 
and B (Gαi1-91Venus) or in the loop connecting helices B and C (Gαi1-121Venus). Venus was also 
introduced into the linker 1 region connecting the α-helical and the GTPase domain of Gαi1 (Gαi1-
60Venus). Inserting Venus in these positions has been shown to affect neither the biochemical and 
catalytic properties of Gαi1, nor the correct expression of and the efficient coupling of these fusion 
proteins to receptors (Gales et al., 2006; Ayoub et al., 2009). BRET was monitored between each tagged 
Gαi1 (Gαi1-60Venus, Gαi1-91Venus and Gαi1-121Venus) and Gβ1-RLuc or Gγ2-RLuc. As shown in Fig. 8B, 
rimonabant significantly increased the basal BRET signal between Gβ1-RLuc or Gγ2-RLuc and Gαi1-
91Venus, and between Gβ1-RLuc or Gγ2-RLuc and Gαi1-121Venus (Fig. 8C). No BRET change was 
detected between Gαi1-60Venus and Gβ1-Rluc or Gγ2-Rluc in the presence of rimonabant (25 µM) (Fig. 
8D). The BRET changes monitored when using Gαi1-91Venus and Gαi1-121Venus as BRET acceptors 
probably reflect a rimonabant-promoted conformational rearrangement within the Gαβγ complex that may 
be differentially monitored depending on the position of the acceptor and donor. 
4. DISCUSSION
At nanomolar concentrations, rimonabant inhibition of basal [
35S]GTPγS binding was interpreted 
either as an inverse agonism at CB1 receptors, i.e. the inhibition of constitutive CB1 receptor activity or 
the suppression of a tonic CB1 mediated activation of G protein by endogenous cannabinoids (Howlett et 
al., 2011; Pertwee 2005 for reviews). Inverse agonist effect induced by nanomolar concentrations has been 
observed in peculiar cell preparations expressing high concentration of the CB1 receptors (Lansdsman et 
al., 1997; MacLennan et al., 1998). However, under our experimental conditions, up to 100 nanomolar 
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concentrations of rimonabant failed to inhibit basal G protein activity. These discrepancies might be 
attributed to the different membranes preparations (i.e. neuroblastoma cells and CHO cells highly 
expressing CB1 receptors versus rodent brain tissues or untransfected CHO) and/or different buffer and 
ionic conditions used.  
On the other hand, numerous studies indicated that rimonabant at micromolar concentration reliably 
reduces GTPγS binding in membrane from rodent, human and heterologous preparations in the presence 
or absence of CB1 receptors (Breivogel et al., 2001; Sim-Selley et al., 2001; Erdozain et al., 2012) and in 
CHO transfected with different GPCRs (Cinar and Szücs 2009; Zador et al., 2014, 2015). 
It has been proposed that at micromolar concentrations rimonabant acts as inverse agonist at a putative 
GPCR receptor for which it has much lower affinity than for CB1 receptors (Breivogel et al., 2001; Cinar 
and Szücs 2009; Erdozain et al., 2012), or that might antagonize a tonic activation of the G protein by 
some endogenous ligand of a GPCR. Accordingly, Savinainem et al. (2003) postulated that rimonabant 
and AM251 reduce GTPγS binding by suppressing a tonic adenosine receptor mediated G-protein 
activation by endogenous adenosine. They based their hypothesis on the finding that in rat cerebellar 
membranes rimonabant and AM251 inhibited adenosine receptors and reduced GTPγS binding similarly 
to all other adenosine receptor antagonists tested. Moreover, neither rimonabant nor AM251 produced 
additional reduction of GTPγS beyond that induced by the specific A1 adenosine receptor DPCX. 
However, it should be pointed out that inhibitory effect of DPCX in cerebellar membranes was not 
reproduced by Erdozain et al (2012) in human cortical membranes. On the other hand different studies 
found that rimonabant and AM251 act as antagonists at opioid receptors (Cinar and Szücs 2009; Zador et 
al., 2014, 2015), suggesting that they may inhibit GTPγS binding by suppressing opioid receptor mediated 
G-protein activation by endogenous opioids.  
The experiments outlined in this paper provide evidence that rimonabant causes a receptor-independent 
inhibition of Gαi/ο activity, which uncouples the G protein from the receptor. Thus, in agreement with 
previous studies (Breivogel et al., 2001; Sim-Selley et al., 2001; Cinar and Szücs 2009; Zador et al., 2014), 
we found that rimonabant inhibited basal [
35S]GTPγS binding at concentrations of 4-5 μM, which are 
much higher than the nanomolar concentrations (0.5-1 nM) required to inhibit CB1 receptors (Rinaldi-
Carmona et al., 1994). According to earlier work (Breivogel et al., 2001; Cinar and Szücs 2009; Erdozain 
et al., 2012) we demonstrated that rimonabant inhibited basal [
35S]GTPγS binding to cortical membranes 
of CB1-KO mice and untransfected CHO cells. Moreover, we found that rimonabant also decreased 
baclofen and quinpirole stimulated [
35S]GTPγS binding to cortical membranes of rats and CB1-KO mice. 
This inhibitory effect was not mediated by the action of rimonabant on CB1, GABAB or D2 receptors 
since it (i) persisted in CB1-KO mice and (ii) binds neither GABAB nor D2 receptors (Rinaldi-Carmona et 
al., 1994).  
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The efficacy of rimonabant in antagonizing baclofen- and quinpirole-induced stimulation of GTP S 
binding was lower than expected by its efficacy in reducing basal GTP S binding. It should be mentioned 
that rimonabant has been shown to inhibit [
35S]GTPγS binding to diverse G protein subunits with 
difference potency (Erdozain et al. 2012), suggesting that baclofen and quinpirole may act on a G-protein 
pool rather resistant to rimonabant inhibition. This possibility is consistent with the finding that 25 μM of 
rimonabant reduced both the potency and the efficacy of baclofen in stimulating GTP S binding. 
BRET data in living cells indicated that rimonabant stabilizes the heterotrimeric state of the G 
protein and prevents the rearrangement of Gαo-βγ subunits induced by GABAB receptor activation. 
Rimonabant has lower potency in the BRET assay than in the GTPγS assay, possibly because the BRET 
assay is performed with intact cells.  
Our results have shown that rimonabant inhibited GPCR-mediated activation of Gαi/o proteins and 
signaling to Gαi/o effectors. Indeed, rimonabant prevented agonist-induced inhibition of forskolin-
stimulated cAMP production in HEK293 cells expressing GABAB or D2 receptors while it failed to inhibit 
Gαs mediated cAMP production in response to D1 receptor activation. Hence, rimonabant acts on the Gαi/o 
subunit of heterotrimeric G proteins.  Future studies are required to evaluate whether or not rimonabant 
inhibits other G proteins, such as Gq/11 and G12. Additionally, rimonabant suppressed baclofen and 
quinpirole-induced outward currents recorded from midbrain dopamine neurons of rats and CB1-KO mice 
as well as GIRK channel gating by GTPγS in CHO cells, confirming that it acts downstream and 
independently of GPCRs.  
AM251, a structural analog of rimonabant, at micromolar concentrations decreased both the basal 
and the baclofen stimulated GTPγS binding to rat cortical membranes and to cell membranes of CHO cells 
stably expressing GABAB receptors. Moreover, AM251 dose-dependently prevented baclofen-induced 
outward currents recorded from midbrain dopamine neurons, suggesting that AM251 acts similarly to 
rimonabant at the same G-protein level. 
Monitoring the BRET signal between probes inserted at various positions in the G protein 
subunits allows us to confirm that rimonabant promotes a receptor-independent conformational 
rearrangement within the Gαβγ complex, which is consistent with the stabilization of the heterotrimeric 
state. However, rimonabant failed to modify the BRET signal when Gαi1 was mutated at position 60, thus 
suggesting a possible site of rimonabant action. Inserting the Venus tag into the linker 1 region of the Gαi1 
protein might disrupt this putative rimonabant binding site. The linker 1 region acts as a hinge during the 
opening of the α-helical domain, allowing GDP to leave the GTPase domain. Alternatively, and according 
to the “gear-shift” model (Cherfils et al., 2003), rimonabant might block the displacement of the α-helical 
domain away from the GTPase region by inhibiting the dissociation between the Gα subunit and the Gβγ 
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dimer, as indicated by the increase in the BRET signal between Gβ1- or Gγ2- and Gαi1-Venus (tagged in 
position 91 and 121). 
Our results indicate that, at micromolar concentrations, rimonabant is not an inverse agonist of the CB1 
receptor, as has been proposed (see Howlett et al., 2011; Pertwee 2005 for reviews), but inhibits the Gαi/o 
protein. The fact that rimonabant directly inhibits the Gαi/o protein is not alternative to the possibility that 
rimonabant may also act at the receptor level, which would contribute (e.g. opioid μ and δ and A1 
adenosine receptor) (Cinar and Szücs 2009; Zador et al., 2014, 2015; Svinainem et al., 2003) to the 
inhibition of the G protein. Blocking of the G protein could, therefore, add to that of the CB1 receptor. 
The inhibitory effect of micromolar concentrations of rimonabant on Gαi/o protein should be 
considered when interpreting its pharmacological effects. Indeed, the vast majority of in vivo experimental 
studies have used doses of rimonabant ranging from 1 to 10 mg/kg (Compton et al., 1996; Terranova et al., 
1996; Gessa et al., 1998; Izzo et al., 1999a, 1999b; Pertwee 2001; Bass et al., 2002; Carai et al., 2004) 
which are expected to result in micromolar brain concentrations (ranging from 0.25 μM to 3 μM) (Barna 
et al., 2009; Tam et al., 2010). Regretfully, tissue and brain levels of rimonabant in clinical studies are not 
available. Rimonabant is a highly hydrophobic molecule with a long half-life (up to 16 days in obese 
subjects) that easily passes the blood brain barrier. It is therefore conceivable that it might reach 
micromolar tissue concentrations during a chronic daily treatment with 20-40 mg, which are the most 
effective doses in the treatment of obesity and nicotine addiction (Pi-Sunyer et al., 2006; Padwal and 
Majumdar 2007; Soyka et al., 2008; Cahill and Ussher 2011). 
Since Gao/i type G proteins are activated by multiple GPCRs, blockade of the G protein may be potentially 
useful in critical conditions, such as cancer and pain, characterized by the dysregulation of a number of 
GPCR signaling pathways (Ahmad and Dray 2004; Dorsam and Gutkind 2007), when targeting a single 
receptor is insufficient for effective treatment. For example, targeting the common Gαi/o protein could be 
therapeutically useful in the treatment of cancers that are characterized by elevated G protein activity 
(Smrcka 2013; Dorsam and Gutkind 2007). Consistently with this proposal, at low micromolar 
concentrations, rimonabant has been shown to exhibit cytotoxic and anti-proliferative effects with 
different cancer cells in vitro, including human lymphoma, human leukemia-derived cell lines, human 
breast cancer and glioma (Bifulco et al., 2007; Malfitano et al., 2007; Ciaglia et al., 2015). Remarkably, 
the antitumor effect has been shown to depend on the inhibition of a cascade of second messengers that 
are dependent on Gαi/o-signaling (New et al., 2007; Ciaglia et al., 2015). However, more in vivo studies 
are needed to determine the toxicity of rimonabant doses inhibiting G protein signaling. 
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FIGURE LEGENDS 
FIGURE 1.Effect of rimonabant on agonist-stimulated G protein activity. Concentration-response curves 
for baclofen (BACL) were performed using [
35S]GTPγS binding assay in cortical membranes of rats (A) 
and of CB1-KO mice (B) in the presence of 5 μM rimonabant (RIM) or vehicle (VEH). (C) 
Concentration-response curves for quinpirole (QUINP) were performed using [
35S]GTPγS binding assays 
in rat striatal membranes in the presence of RIM or VEH. Data (A-C) are representative of a typical 
experiment performed in triplicate, and are expressed as percentage normalized to the respective basal 
value ± S.E.M. Non-visible S.E.M. is within the symbol. 
FIGURE 2. Effects of rimonabant and AM251 on basal [
35S]GTPγS binding in rat frontal cortex 
membranes, in CHO-GABAB cell membranes and on baclofen-induced stimulation of  [
35S]GTPγS
binding in rat frontal cortex membranes. AM251 (AM) and rimonabant (RIM) at micromolar 
concentrations produce a significant inhibition of basal GTPγS binding both in membranes prepared from 
rat frontal cortex (A) and CHO-GABAB cells (B). Both compounds (C) significantly reduce the agonist 
effect induced by a submaximal concentration of baclofen (10 μM). Horizontal dotted lines indicate 
baseline values and the degree of stimulation with the agonist baclofen (BACL), respectively. Data, 
expressed as dpm, represent the mean ± SEM calculated from at least four independent experiments, each 
performed in triplicate **p<0.01, vs Basal and vs BACL 10 μM, Tukey test. 
FIGURE 3. Rimonabant stabilized the heterotrimeric Gαi/o protein complex and prevented G protein 
rearrangements induced by the GABAB receptor agonist baclofen. (A) Illustration of the conformational 
change during G protein activation that is monitored by BRET measurements in CHO cells expressing 
GABAB receptors. Rluc probe in the Gαo subunit is shown in blue and the Venus probe on the Gγ2 subunit 
is shown in yellow. (B) BRET kinetics measured in the presence of rimonabant (RIM) or the vehicle 
(VEH). Baclofen (BACL) (10 µM), applied after 29 cycles of reading (≈25 sec), decreased the BRET 
signal due to conformational rearrangement of the Gαo-RLuc and Gγ2–Venus subunits. The curves were 
fitted with plateau followed by one-phase decay equation using Prism GraphPad software. The BRET 
ratio was calculated as the ratio of light emitted by Venus (530–570 nm) over the light emitted by RLuc 
(370–470 nm) and corrected by subtracting ratios obtained with the RLuc fusion protein alone. The results 
were expressed in mBRET units (BRET x 1000). Data points are presented as triplicates from 
one representative experiment. (C) Bar graph of the change in basal BRET is presented as mean ± SEM of 
6 experiments. *p<0.05, **p<0.01, ***p<0.001,****p<0.0001 vs VEH, Bonferroni test. (D) Bar graph of 
the change in ΔBRET is presented as a mean ± SEM of 6 experiments. Horizontal dotted lines indicate 
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baseline values and the ΔBRET (%) values calculated in the presence of Baclofen *p<0.05, **p<0.01 vs 
BACL, Bonferroni test.  
FIGURE 4. Effects of rimonabant on GABAB and D2 receptor signaling pathways: BRET kinetic 
measurements of cAMP responses using a CAMYEL sensor. (A) BRET signal (expressed as YFP/RLuc 
ratio), measured in the presence of rimonabant (RIM) or the vehicle (VEH) in HEK-293 cells transiently 
co-expressing the CAMYEL sensor and Myc-GABAB1a and Myc-GABAB2. 0.5 μM forskolin (FORSK) 
was applied after 150 seconds of reading, baclofen (BACL) 10 μM was applied after 500 seconds. The 
BRET recovery phases are shown fitted to a double exponential function (inset). Data points are presented 
as triplicates from one representative experiment. (B) Bar graph of the amplitude-weighted mean time 
constant (tau CAMYEL activity) was obtained by fitting BRET recovery phase to a double exponential 
function. Data are presented as mean ± SEM of 5 experiments. *p<0.05 and  ***p<0.001 vs BACL alone, 
Bonferroni test. (C) Bar graph of the change in ΔBRET is presented as mean ± SEM of 5 experiments, 
performed in triplicate. **p<0.01, ***p<0.001 vs BACL alone, Bonferroni test. (D) BRET signal 
(expressed as YFP/RLuc ratio), measured in the presence of RIM or VEH in HEK-293 cells transiently 
co-expressing CAMYEL sensor and HA-D2. 0.5 μM forskolin was applied after 150 seconds of reading, 
quinpirole (QUINP) 10 μM was applied after 500 seconds. The BRET recovery phases are shown fitted to 
a double exponential function (inset). Data points are presented as triplicates from one representative 
experiment. (E) Bar graph of the amplitude-weighted mean time constant (tau CAMYEL activity) was 
obtained by fitting the BRET recovery phase to a double exponential function. Data are presented as mean 
± SEM of 5 experiments. *p<0.05 vs QUINP alone, Bonferroni test. (F) Bar graph of the change in 
ΔBRET is presented as mean ± SEM of 5 experiments, performed in triplicate. Horizontal dotted lines 
indicate tau values and ΔBRET (%) values calculated in the presence of baclofen and quinpirole, 
respectively. **p<0.01, vs QUINP alone, Bonferroni test 
FIGURE 5. Effects of rimonabant on D1 receptor signaling pathways: BRET kinetic measurements of 
cAMP responses using a CAMYEL sensor. (A) BRET signal (expressed as YFP/RLuc ratio), measured in 
the presence of rimonabant (RIM) or the vehicle (VEH) in HEK-293 cells transiently co-expressing the 
CAMYEL sensor and HA-D1. A68293 (10 µM) was applied after 25 seconds of reading. Data are 
presented as triplicates from one representative experiment. The curves were fitted with Plateau followed 
by one-phase decay equation using Prism GraphPad software. (B) Bar graph of the amplitude-weighted 
mean time constant (tau CAMYEL activity) was obtained by fitting the BRET recovery phase to a double 
exponential function. Data are presented as mean ± SEM of 5 experiments. (C) Bar graphs are calculated 
as the difference between the basal and the plateau of BRET signal. Horizontal dotted lines indicate tau 
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values and ΔBRET (%) values calculated in the presence of A68293. Data are the mean ± SEM of 5 
experiments. ns= not significant, Bonferroni test. 
FIGURE 6. Effect of rimonabant on K
+
 currents evoked by GABAB and D2 receptor activation. Time
course graphs illustrate the average effects of baclofen (10 μM, A-B-C), quinpirole (1 μM, D) and 
rimonabant (10 μM) on the holding current (Ihold) of dopamine cells ex vivo. When a voltage-clamped 
(Vholding= -70 mV) rat dopamine neuron is perfused with baclofen (BACL; 10 μM, gray bar) an outward 
current is evoked that is reproducible over time (A) unless rimonabant is applied (B; RIM; 10 μM, black 
bar). The inset in panel B shows that BACL (black line) caused a 132 pA outward current in voltage-
clamp, which was abolished in the presence of RIM (RIM’s effect on Iholding is superimposed in light gray 
for comparison). The horizontal bar represents the time of BACL application. Calibration bar: 100 pA, 5 
min. (C) RIM also prevents BACL-induced outward current in CB1-KO mouse dopamine neurons. (D) 
RIM blocks the outward current evoked upon activation of D2 receptors by quinpirole (QUINP; 1 μM, 
gray bar). (E, F) Effect of different concentrations of AM251 (AM), a structural analogue of rimonabant, 
on K
+
 currents evoked by GABAB receptor activation. Time course graphs illustrate the average effects of
BACL (10 μM, E and F) on the holding current (Ihold) of dopamine cells ex vivo. BACL (10 μM, gray bar) 
induces an outward current that is reproducible in the presence of a low concentration of AM (2 µM, AM 
2) (E) but blunted at higher concentrations (20 µM, AM 20) (F). All data are normalized to the respective
baseline current (5 min). Black bars show the time of superfusion of either VEH, RIM or AM. SEM bars 
are smaller than symbols in some cases. *p<0.05, **p<0.01, ***p<0.0001, paired t-test with Welch’s 
correction. 
FIGURE 7. Rimonabant slowed the onset of GTPγS-induced GIRK currents in CHO cells. (A) 
Representative traces of Kir3 currents activated by intracellular perfusion of GTPγS (0.6 mM) and 
recorded at -50 mV in transfected CHO cells expressing GIRK1/2 channels with 10 µM of RIM or with 
VEH. Note the slowly rising K
+
 current in the presence of RIM. (B) Bar graph summarizing the densities 
(expressed as ratios between maximal amplitudes and the cell capacitances) and the 10% to 90% rise time 
of GTPγS-induced responses. Data are represented as mean ± SD of 5 VEH and 4 RIM recordings. **p < 
0.01,  ***p< 0.001; vs VEH; Student’s t test. 
FIGURE 8. Effect of rimonabant on Gαi1-Gβγ subunits rearrangement in HEK-293 cells. (A) Schematic 
representation of the different tags on the G protein subunits. Rluc probes in Gβ1 and in the Gγ2 C-
terminal are shown in blue and Venus probes on the Gαi1 subunit are shown in yellow. BRET 
measurements in HEK-293 cells co-expressing Gβ1-RLuc or Gγ2-RLuc and either Gαi1-91Venus (B), or 
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Gαi1-121Venus (C) or Gαi1-60Venus (D) subunits. The cells were incubated with RIM (rimonabant, 25 
µM) (grey bars) or with the vehicle (black bars) for 1h at 37°C. Data are presented as a mean ± SEM of 5 
experiments. *p<0.05, **p<0.01, ***p<0.0001 ns= not significant, Bonferroni test. 
FIGURE SUPPL. 1 Effect of rimonabant on baclofen-stimulated [
35S]GTPγS binding in rat cortex 
membranes.  At 25 μM rimonabant (RIM) inhibited the baclofen-stimulated GTPγS binding with an 
pEC50 of 3.79 (EC50 161 μM) and decreased its maximal  (Emax  ≈125). Data shown are representative 
of a typical experiment performed in triplicate, expressed as percentage normalized to the respective basal 
value ± S.E.M. 
FIGURE SUPPL. 2 
Normalized BRET ratio measured in the presence of rimonabant (RIM 50 µM) or vehicle (VEH). 
Baclofen (BACL) (10 µM), applied after 29 cycles of reading (≈25 sec), decreased the BRET signal due to 
a conformational rearrangement of the Gαo-RLuc and Gγ2–Venus subunits. The curves were fitted with 
plateau followed by one-phase decay equation using Prism GraphPad software. The BRET ratio was 
calculated as the ratio of light emitted by Venus (530–570 nm) over the light emitted by RLuc (370–470 
nm) and corrected by subtracting ratios obtained with the RLuc fusion protein alone. The data were 
expressed as BRET ratio and normalized to the baseline. Data points are presented as triplicates from 
one representative experiment. (B) Raw traces of the Rluc signal recorded at 370-470 nm, measured 
in the presence of increasing concentrations of rimonabant (RIM) or vehicle control (VEH) in 
CHO cells expressing GABAB receptors, Gαo-Rluc and Gγ2-HA. Injection of BACL (10 µM) 
produced similar injection artifacts in all traces. Data points from a representative experiment (n 
=3) are expressed as relative luminescence units (RLU). 
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TABLE 1 
Rimonabant induced inhibition of basal [
35S]GTPγS binding in native and recombinant systems. 
 IC50 (μM)    Maximal Inhibition (%) 
Rat cortex 3.9 ± 0.4 48 ± 2.6 
Rat striatum 3.7 ± 0.5 50 ± 3.3 
CB1 KO mice (cortex) 12.1 ± 2.1 38 ± 1.5 
WT littermate mice (cortex) 12.6 ± 2.1 36 ± 1.0 
GABAB KO mice (cortex) 4.3 ± 1.2 50 ± 1.4 
WT littermate mice (cortex) 3.9 ± 0.8 48 ± 1.7 
CHO-GABAB cells 6.9 ± 1.1 27 ± 1.9 
CHO-D2 cells 10.5 ± 4.6 24 ± 2.0 
Parental CHO cells 7.6 ± 2.7 22 ± 1.7 
Concentration response curves for rimonabant  (RIM) were performed in native or in recombinant systems 
(Chinese Hamster Ovary, CHO cells). RIM decreased basal [
35S]GTPγS binding independently of the 
presence or absence of the GPCR. Data are expressed as percentage stimulation over basal [
35S]GTPγS 
binding, measured in the absence of RIM and defined as 100%, as described in material and methods. 
IC50 and Imax are calculated with GraphPad using non-linear regression analysis of the concentration-
response curve performed in the brain or in CHO membrane preparation. Maximal RIM inhibition was 
expressed as the percentage of inhibition relative to 100%. WT: wild type 
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Table 2: Rimonabant decreased GABAB and D2 receptor agonists-stimulated [
35S]GTPγS binding in rat,
mouse cortical and striatal membranes. 
EC50 
(μM) 
pEC50 
(-Log M)    (95% CI) 
Maximal effect 
relative to 
BACL or 
QUINP (%) 
Rat cortex BACL 7.30 ± 1.10 5.15 ± 0.06 4.96-5.34  100.00 ± 5.06 
Rat cortex BACL +RIM 11.32 ±1.00* 4.91 ± 0.03* 4.84-5.06    94.48 ± 3.68 
CB1-KO mice (cortex) BACL 2.48 ± 0.64 5.65 ± 0.11 5.29-6.01 100.00 ± 3.08 
CB1-KO mice (cortex) BACL+ RIM 4.26 ± 0.17+ 5.37 ± 0.02+ 5.32-5.42   94.83 ± 3.27 
Rat striatum QUINP 3.36 ± 0.14 5.47 ± 0.02 5.39-5.55  100.00 ± 6.59 
Rat striatum QUINP + RIM 9.17 ± 1.85& 5.06 ± 0.09& 4.65-5.46  105.50 ± 4.49 
The selective GABAB and D2 receptor agonists were tested alone or in combination with rimonabant (RIM) (5 
μM). RIM decreased the potency of baclofen (BACL)- and quinpirole (QUINP)-stimulated [35S]GTPγS binding in 
rat cortical and striatal membranes and in membranes of CB1-KO mice. RIM did not modify the maximal efficacy 
of agonists. Data are expressed as percentage stimulation over their respective baseline values and represent the 
mean ± SEM calculated from at least four independent experiments, each performed in triplicate. Data are fitted 
with the GraphPad Prism 6.0 software using nonlinear regression and sigmoidal curve fitting to obtain EC50, 
pEC50 and maximal effect values. As the maximal effect of BACL and QUINP alone differed between 
experiments, data are normalized to the maximal effect of BACL and QUINP under control conditions (=100). CI; 
values represent 95 % confidence intervals of values from four experiments; *p < 0.05 vs baclofen (Rat Cortex) ; 
+
p < 0.05 vs baclofen (CB1-KO Mice), 
&
p < 0.05 vs quinpirole (Rat Striatum); unpaired Student’s t-test. 
32 
FIGURE 1 
33 
FIGURE 2 
A
C
B
BA
SA
L
+ 
RI
M
 1
0 
µM
+ 
AM
 1
0 
µM
20000
15000
10000
5000
0
[
5
3
 
g
ni
d
ni
b 
S
γ
P
T
G]
S
D
P
M **
**
BA
SA
L
+ 
RI
M
 1
0 
µM
+ 
AM
 1
0 
µM
4000
3000
2000
1000
0
[
5
3
 
g
ni
d
ni
b 
S
γ
P
T
G]
S
D
P
M
** **
20000
15000
10000
5000
0
[
5
3
 
g
ni
d
ni
b 
S
γ
P
T
G]
S
D
P
M
BA
CL
 1
0 
µM
+ 
RI
M
 1
0 
µM
+ 
AM
 1
0 
µM
**
**
  34 
FIGURE 3 
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FIGURE 4 
A
C
B
200 sec
B
R
E
T
0.5 µM FORSK
10 µM BACL
1.6
1.5
1.4
1.2
1.3
***
70
60
50
40
30
20
10
0
BA
CL
 1
0 
µM
+ 
RI
M
 2
5 
µM
+ 
RI
M
 5
0 
µM
***
**
110
100
90
80
70
60
50
40
30
20
10
0
Δ
B
R
E
T
 (
%
)
BA
CL
 1
0 
µM
+ 
RI
M
 2
5 
µM
+ 
RI
M
 5
0 
µM
1.45
1.50
1.55
1.60
1.65
D
0.5 µM FORSK
10 µM QUINP
B
R
E
T
10
20
30
40
50
60
*
E
Q
UI
NP
 1
0 
µM
+ 
RI
M
 2
5 
µM
+ 
RI
M
 5
0 
µM
F
0
15
30
45
60
75
90
105
**
Δ
B
R
E
T
 (
%
)
Q
UI
NP
 1
0 
µM
+ 
RI
M
 2
5 
µM
+ 
RI
M
 5
0 
µM
VEH
+ RIM 50 µM
VEH
+ RIM 50 µM
  
ta
u
 C
A
M
Y
E
L
 a
c
ti
v
it
y
(s
e
c
)
ta
u
 C
A
M
Y
E
L
 a
c
ti
v
it
y
(s
e
c
)
*
50 sec
200 sec
50 sec
36 
FIGURE 5 
0
10
20
30
40
ns
ns
0
0.1
0.2
0.3
0.4
0.5
ns
ns
A
B
C
10 µM A68293
0 20 40 60 80
Time (sec) 
B
R
E
T
1.6
1.5
1.4
1.2
1.3
1.1
A6
82
93
 1
0 
µM
+ 
RI
M
 2
5 
µM
+ 
RI
M
 5
0 
µM
A6
82
93
 1
0 
µM
+ 
RI
M
 2
5 
µM
+ 
RI
M
 5
0 
µM
Δ
B
R
E
T
 (
%
)
VEH
+RIM 50 µM
 t
a
u
 C
A
M
Y
E
L
 a
c
ti
v
it
y
(s
e
c
)
  37 
FIGURE 6  
 
 
  
A B
CB1 -/-
DC
VEHBACL
BACL
)
A
p(       I  
e
s
n
o
p
s
er 
d
e
zil
a
mr
o
N
300
200
h
o
ld
100
-100
-200
0
0 10 20 30 40
Time (min)
RIMBACL
BACL
)
A
p(       I 
e
s
n
o
p
s
er 
d
e
zil
a
mr
o
N
300
200
dl
o
h
100
-100
-200
0
0 10 20 30 40
Time (min)
RIMBACL
BACL
)
A
p(        I 
e
s
n
o
p
s
er 
d
e
z il
a
m r
o
N
300
200
h
o
ld
100
-100
-200
0
0 10 20 30 40
Time (min)
0 10 20 30 40
Time (min)
)
A
p(        I 
e
s
n
o
p
s
er 
d
e
zi l
a
m r
o
N
300
200
dl
o
h
100
-100
-200
0
RIMQUINP
QUINP
***
**
*
**
0 10 20 30 40
Time (min)
0 10 20 30 40
Time (min)
)
A
p(       I 
e
s
n
o
p
s
er  
d
e
z il
a
mr
o
N
300
200
h
o
ld
100
-100
-200
0
)
A
p(       I  
e
s
n
o
p
s
er 
d
e
zil
a
mr
o
N
300
200
dl
o
h
100
-100
-200
0
AM 2BACL
BACL
AM 20BACL
BACL
E F
38 
FIGURE 7 
40 pA
2 min
VEH
R I M
whole-cell
recording I 
d
e
n
s
it
y
 (
p
A
/p
F
)
1
0
-9
0
%
 ris
e
 tim
e
 (s)
0.0
0.5
1.0
1.5
2.0
0
100
200
300
400
500***
**
GTPγS
B
VE
H
+ 
RI
M
 1
0 
µM
VE
H
+ 
RI
M
 1
0 
µM
A
39 
FIGURE 8 
0
20
40
60
80
100
120
140
Gαi-91Venus
**
*
0
20
40
60
80
100
120
Gαi-121Venus
***
*
0
10
20
30
40
Gαi-60Venus
ns
ns
A B
C D
m
B
R
E
T
be
ta
-R
lu
c
ga
m
m
a-
Rl
uc
be
ta
-R
lu
c
ga
m
m
a-
Rl
uc
be
ta
-R
lu
c
ga
m
m
a-
Rl
uc
m
B
R
E
T
m
B
R
E
T
40 
FIGURE SUPPL. 1 
41 
FIGURE SUPPL. 2. 
A
N
o
rm
a
liz
e
d
 B
R
E
T
B
VEH
+ RIM 50 µM
150
100
50
0
0 20 40 60 80
Time (sec)
10 µM BACL
VEH
+ RIM 5 µM
+ RIM 10 µM
+ RIM 25 µM
+ RIM 50 µM
200000
0 20 40 60 80
Time (sec)
100
220000
240000
260000
280000
R
L
U
 (
3
7
0
-4
7
0
 n
m
)
10 µM BACL
TABLE 1 
Rimonabant induced inhibition of basal [
35S]GTPγS binding in native and recombinant systems. 
          IC50 (μM)  Maximal Inhibition (%) 
Rat cortex 3.9 ± 0.4 48 ± 2.6 
Rat striatum 3.7 ± 0.5 50 ± 3.3 
CB1 KO mice (cortex) 12.1 ± 2.1 38 ± 1.5 
WT littermate mice (cortex) 12.6 ± 2.1 36 ± 1.0 
GABAB KO mice (cortex) 4.3 ± 1.2 50 ± 1.4 
WT littermate mice (cortex) 3.9 ± 0.8 48 ± 1.7 
CHO-GABAB cells 6.9 ± 1.1 27 ± 1.9 
CHO-D2 cells 10.5 ± 4.6 24 ± 2.0 
Parental CHO cells 7.6 ± 2.7 22 ± 1.7 
Concentration response curves for rimonabant  (RIM) were performed in native or in recombinant systems 
(Chinese Hamster Ovary, CHO cells). RIM decreased basal [
35S]GTPγS binding independently of the 
presence or absence of the GPCR. Data are expressed as percentage stimulation over basal [
35S]GTPγS 
binding, measured in the absence of RIM and defined as 100%, as described in material and methods. IC50 
and Imax are calculated with GraphPad using non-linear regression analysis of the concentration-response 
curve performed in the brain or in CHO membrane preparation. Maximal RIM inhibition was expressed as 
the percentage of inhibition relative to 100%. WT: wild type 
Table 1
Table 2: Rimonabant decreased GABAB and D2 receptor agonists-stimulated [
35S]GTPγS binding in
rat, mouse cortical and striatal membranes. 
EC50 
(μM) 
pEC50 
(-Log M)          (95% CI) 
Maximal effect 
relative to BACL 
or QUINP (%) 
Rat cortex BACL 7.30 ± 1.10 5.15 ± 0.06 4.96-5.34  100.00 ± 5.06 
Rat cortex BACL +RIM 11.32 ±1.00
*
 4.91 ± 0.03
*
 4.84-5.06    94.48 ± 3.68 
CB1-KO mice (cortex) BACL 2.48 ± 0.64 5.65 ± 0.11 5.29-6.01 100.00  ± 3.08 
CB1-KO mice (cortex) BACL+ RIM 4.26 ± 0.17
+
 5.37 ± 0.02
+
 5.32-5.42   94.83  ± 3.27 
Rat striatum QUINP 3.36 ± 0.14 5.47 ± 0.02 5.39-5.55  100.00 ± 6.59 
Rat striatum QUINP + RIM 9.17 ± 1.85
&
 5.06 ± 0.09
&
 4.65-5.46  105.50 ± 4.49 
 The selective GABAB and D2 receptor agonists were tested alone or in combination with rimonabant (RIM) 
(5 μM). RIM decreased the potency of baclofen (BACL)- and quinpirole (QUINP)-stimulated [35S]GTPγS 
binding in rat cortical and striatal membranes and in membranes of CB1-KO mice. RIM did not modify the 
maximal efficacy of agonists. Data are expressed as percentage stimulation over their respective baseline 
values and represent the mean ± SEM calculated from at least four independent experiments, each performed 
in triplicate. Data are fitted with the GraphPad Prism 6.0 software using nonlinear regression and sigmoidal 
curve fitting to obtain EC50, pEC50 and maximal effect values. As the maximal effect of BACL and QUINP 
alone differed between experiments, data are normalized to the maximal effect of BACL and QUINP under 
control conditions (=100). CI; values represent 95 % confidence intervals of values from four experiments; *p 
< 0.05 vs baclofen (Rat Cortex); 
+
p < 0.05 vs baclofen (CB1-KO Mice), 
&
p < 0.05 vs quinpirole (Rat 
Striatum); unpaired Student’s t-test.   
Table 2
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